Joseph Schwartz
Stock Analyst at Leerink Partners
(1.74)
# 3,060
Out of 4,784 analysts
143
Total ratings
33.06%
Success rate
-1.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $11.42 | +145.18% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $19.68 | +103.25% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.52 | +2,611.60% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $3.01 | +32.89% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.39 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $4.32 | +177.78% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $2.30 | +247.83% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $1.73 | +246.82% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.30 | +577.74% | 5 | Mar 14, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.28 | -21.88% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $4.21 | +42.52% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $54.24 | -11.50% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $15.80 | +13.92% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $11.93 | +67.64% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $31.15 | +9.15% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $71.44 | +81.97% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $70.41 | +127.24% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $154.68 | +5.38% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.17 | +754.70% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.48 | +2,129.73% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $8.29 | +44.75% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $37.82 | +185.56% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $77.99 | -35.89% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $34.73 | +12.29% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.15 | +247.83% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $23.27 | +28.92% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $31.60 | +58.23% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $48.88 | -38.63% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $12.47 | +349.08% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.43 | +66.07% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.40 | +757.14% | 2 | Sep 26, 2017 |
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $11.42
Upside: +145.18%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $19.68
Upside: +103.25%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.52
Upside: +2,611.60%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $3.01
Upside: +32.89%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.39
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $4.32
Upside: +177.78%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.30
Upside: +247.83%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $1.73
Upside: +246.82%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.30
Upside: +577.74%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.28
Upside: -21.88%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $4.21
Upside: +42.52%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $54.24
Upside: -11.50%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $15.80
Upside: +13.92%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $11.93
Upside: +67.64%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $31.15
Upside: +9.15%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $71.44
Upside: +81.97%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $70.41
Upside: +127.24%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $154.68
Upside: +5.38%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.17
Upside: +754.70%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.48
Upside: +2,129.73%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $8.29
Upside: +44.75%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $37.82
Upside: +185.56%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $77.99
Upside: -35.89%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $34.73
Upside: +12.29%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.15
Upside: +247.83%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $23.27
Upside: +28.92%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $31.60
Upside: +58.23%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $48.88
Upside: -38.63%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $12.47
Upside: +349.08%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $8.43
Upside: +66.07%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.40
Upside: +757.14%